N/A
Completed N=41
Buprenorphine Treatment Engagement and Overdose Prevention
Source: ClinicalTrials.gov NCT03677986 ↗Enrolled (actual)
41
Serious AEs
0.0%
Results posted
Feb 2024
Primary outcomePrimary: Buprenorphine Treatment Adherence — 19.7; 16.1 percentage of urine samples — p=0.914
Summary
Office-based buprenorphine could be expanded to treat many of the opioid users who are not in treatment and who are at great risk for opioid overdose, but effective approaches are needed to help individuals with opioid use disorder initiate and remain in office-based buprenorphine treatment. Investigators propose to develop and pilot test a novel intervention that will combine video-based directly observed therapy and incentives to promote buprenorphine treatment engagement and adherence in out-of-treatment opioid users.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Buprenorphine Treatment Adherence |
19.7; 16.1 | 0.914 |
| SECONDARY Linkage to Treatment |
— | — |
Eligibility Criteria
Inclusion Criteria
- opioid use disorder
Exclusion Criteria
- current suicidal/homicidal ideation
- severe psychiatric disorder
Data sourced from ClinicalTrials.gov (NCT03677986). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.